Hydroxytyrosol
PolyphenolPreclinicalAlso known as: HT, 3,4-DHPEA, DOPET, Hytolive, Benolea
Hydroxytyrosol (3,4-dihydroxyphenylethanol, abbreviated HT or 3,4-DHPEA) is the smallest of the natural phenolic compounds produced by the olive tree and — pharmacologically — the single most important molecule in the olive polyphenol family. Chemically, hydroxytyrosol is a catechol: a benzene ring substituted with two adjacent hydroxyl groups at the 3' and 4' positions, connected through a two-carbon ethyl bridge to a terminal hydroxyl.
Overview
At A Glance
Hydroxytyrosol's pharmacology organizes around six interlocking mechanisms that together explain the cardiovascular, metabolic, neuroprotective, and longevity signals attributed to olive polyphenol intake.…
Mechanism of Action
Hydroxytyrosol's pharmacology organizes around six interlocking mechanisms that together explain the cardiovascular, metabolic, neuroprotective, and longevity signals attributed to olive polyphenol intake.
(1) Direct antioxidant activity and LDL oxidation protection — the EFSA-claim mechanism. Hydroxytyrosol is a catechol with two adjacent phenolic hydroxyl groups on a benzene ring, a structural arrangement that allows extremely rapid donation of phenoxyl hydrogens to peroxyl, hydroxyl, superoxide, and peroxynitrite radicals. The bond dissociation energy of the phenolic O–H in a catechol is lower than in a monophenol, and the resulting ortho-semiquinone radical is stabilized by hydrogen bonding between the adjacent hydroxyl and the phenoxyl radical. This is the same chemistry that gives catecholamines their pro-oxidant / antioxidant duality in physiology. In the context of LDL particles, hydroxytyrosol partitions between the aqueous phase and the phospholipid-surfactant interface of the lipoprotein, intercepting peroxyl radicals generated during lipid peroxidation and halting the propagation cycle that converts native LDL to oxidized LDL. The Covas 2006 EUROLIVE trial (PMID 16954359) demonstrated that 25 mL/day of high-polyphenol EVOO (366 mg/kg total polyphenols, equivalent to ~18 mg/day hydroxytyrosol-equivalents) reduced circulating oxidized LDL markers significantly more than the same volume of low-polyphenol refined olive oil (2.7 mg/kg polyphenols) over three 3-week crossover periods in 200 healthy men — establishing a clear dose-response for olive polyphenol intake on a hard mechanistic cardiovascular biomarker. This is the mechanism on which the 2012 EFSA health claim rests.
(2) Nrf2/Keap1/ARE activation and endogenous antioxidant enzyme upregulation. Hydroxytyrosol covalently modifies cysteine residues on Keap1 (Kelch-like ECH-associated protein 1), the cytosolic inhibitor of Nrf2 (nuclear factor erythroid 2-related factor 2). This stabilizes Nrf2, allowing its nuclear translocation to antioxidant response elements (AREs) in the promoters of phase-II detoxification and antioxidant enzyme genes. Downstream, this upregulates heme oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase-1 (NQO1), glutathione-S-transferases (GSTs), γ-glutamylcysteine ligase (GCL, rate-limiting for glutathione synthesis), thioredoxin reductase, and the superoxide dismutases (SOD1, SOD2). The net effect is an endogenous antioxidant boost that persists beyond the brief circulating lifetime of hydroxytyrosol itself — a "priming" of cellular defenses against subsequent oxidative challenge. This Nrf2 mechanism is shared with sulforaphane, which is a substantially more potent Nrf2 activator than hydroxytyrosol; the two can be stacked for additive effect, though sulforaphane carries the Nrf2 signal while hydroxytyrosol contributes direct radical scavenging plus a modest Nrf2 effect.
(3) Endothelial nitric oxide synthase (eNOS) upregulation and endothelial function improvement. Hydroxytyrosol upregulates eNOS transcript and protein expression in endothelial cells, enhances eNOS phosphorylation at the activating Ser1177 residue, and reduces NADPH-oxidase-derived superoxide that would otherwise scavenge NO and form peroxynitrite. The net effect is improved NO bioavailability and enhanced flow-mediated dilation. Crossover studies with high-polyphenol EVOO (Storniolo and colleagues; various Spanish and Italian cohorts) have documented modest but consistent 1–3% absolute increases in brachial-artery FMD with daily EVOO intake at PREDIMED-range doses over 2–8 weeks. The eNOS mechanism overlaps with hesperidin, L-citrulline, dietary nitrate (beetroot), and cocoa flavanols — these eNOS-active compounds can be stacked for additive vascular effects, though clinical trials have not yet formally compared stacked versus single-agent eNOS-support combinations head-to-head.
(4) Anti-inflammatory activity via NF-κB inhibition. Hydroxytyrosol inhibits NF-κB activation in monocytes, macrophages, endothelial cells, and adipocytes, reducing transcription of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), chemokines (MCP-1, CXCL1), adhesion molecules (VCAM-1, ICAM-1, E-selectin), and acute-phase reactants (CRP). The clinical magnitude is modest but reproducible — PREDIMED participants in the EVOO arm showed small but statistically significant reductions in hsCRP, IL-6, and soluble ICAM-1 over the 5-year intervention, and smaller RCTs with direct hydroxytyrosol isolates show similar signals over 4–12 weeks. Oleocanthal — the related olive secoiridoid responsible for the peppery cough sensation in fresh high-polyphenol EVOO — adds direct COX-1 and COX-2 inhibition to the olive polyphenol matrix (Beauchamp 2005), a mechanism independent of hydroxytyrosol but that contributes to the anti-inflammatory signal of the whole-food olive intervention.
(5) Mitochondrial biogenesis, mitophagy, and mitochondrial antioxidant defenses. Hydroxytyrosol upregulates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial biogenesis, and the mitochondrial transcription factor TFAM. It also activates AMPK (5'-AMP-activated protein kinase), which triggers autophagy and mitophagy — the selective removal of damaged mitochondria. Preclinical studies in cultured cells and rodent models show hydroxytyrosol increases mitochondrial mass, improves mitochondrial membrane potential, enhances oxygen consumption, and reduces mitochondrial ROS production. This mitochondrial-support signal overlaps with CoQ10, PQQ, nicotinamide riboside, and urolithin-a — each hitting a different mitochondrial-support node (respiratory-chain cofactor, mitochondrial biogenesis agonist, NAD+ precursor, mitophagy inducer respectively), and the combination is more physiologically complete than any single agent.
(6) Pharmacokinetics and metabolic disposition. Oral hydroxytyrosol is absorbed with high bioavailability (40–90% depending on the study, matrix, and analytical methodology). Cmax is reached within 0.5–1 hour of oral intake. Circulating hydroxytyrosol is rapidly conjugated in enterocytes and liver by UGT (glucuronidation) and SULT (sulfation) enzymes to form hydroxytyrosol-4'-glucuronide, hydroxytyrosol-3'-sulfate, and minor amounts of 3'-O-methyl-hydroxytyrosol (homovanillic alcohol). The conjugates are deconjugated in target tissues by β-glucuronidase and sulfatases, delivering free hydroxytyrosol intracellularly for antioxidant and signaling effects. Elimination half-life of the parent and conjugates is 1–4 hours, with urinary excretion as the primary route. This rapid turnover — plus the modest catechol-O-methyltransferase (COMT) inactivation pathway shared with catecholamines — means hydroxytyrosol achieves only brief systemic peaks and requires divided dosing for sustained plasma levels. The practical implication is that daily consistent intake (from food or supplementation) is more important than single-dose levels — the Nrf2 priming effect and cumulative antioxidant enzyme upregulation are the durable benefit, not the transient radical-scavenging window of an individual dose.
Cross-talk with other polyphenols and cofactors. Hydroxytyrosol regenerates α-tocopherol (vitamin E) by reducing the tocopheroxyl radical back to active tocopherol, functioning synergistically with the lipid-soluble antioxidant system — this is one of the reasons EVOO (which contains both hydroxytyrosol/oleuropein AND α-tocopherol in the same lipid matrix) is more than the sum of its parts mechanistically. HT also cooperates with ascorbate (vitamin C) in the aqueous phase, with glutathione in the intracellular compartment, and with CoQ10 in the mitochondrial inner membrane. The integrated antioxidant network is what delivers durable oxidative protection, not any single molecule in isolation.
Overview
Hydroxytyrosol (3,4-dihydroxyphenylethanol, abbreviated HT or 3,4-DHPEA) is the smallest of the natural phenolic compounds produced by the olive tree and — pharmacologically — the single most important molecule in the olive polyphenol family. Chemically, hydroxytyrosol is a catechol: a benzene ring substituted with two adjacent hydroxyl groups at the 3' and 4' positions, connected through a two-carbon ethyl bridge to a terminal hydroxyl. This catechol motif is what makes hydroxytyrosol so biologically active — the same structural feature that gives catecholamines (dopamine, norepinephrine, epinephrine) their extraordinary chemical reactivity, and the same feature that gives EGCG, quercetin, and other catechol-bearing polyphenols their antioxidant kinetics. Hydroxytyrosol differs from dopamine by a single nitrogen: it is the "dopamine without the amine," a biosynthetic cousin of our endogenous neurotransmitters. This structural simplicity gives hydroxytyrosol exceptional radical-scavenging kinetics, tight affinity for LDL particles, ready crossing of the blood-brain barrier, and a pharmacology that bridges the polyphenol and catecholamine worlds.
Hydroxytyrosol is found in olive leaves (up to several hundred mg/kg), olive fruit (200–4,000 mg/kg depending on cultivar and ripeness), olive mill wastewater (a major agricultural waste product that is one of the richest natural hydroxytyrosol sources and a focus of "circular bioeconomy" extraction technology), and — critically — in extra-virgin olive oil, where it appears both as free hydroxytyrosol and as the hydrolysis product of oleuropein during oil pressing, storage, and gastric passage. Premium high-polyphenol EVOO delivers 10–30 mg/kg of free hydroxytyrosol plus 100–500 mg/kg of hydroxytyrosol-releasing secoiridoids (oleuropein and oleuropein aglycone), which are hydrolyzed to hydroxytyrosol during digestion. This is why olive polyphenol content is reported as "hydroxytyrosol and its derivatives" in both EFSA regulation and the scientific literature — the hydroxytyrosol equivalent is the biologically meaningful unit.
BodyHackGuide covers hydroxytyrosol as the most clinically validated polyphenol molecule in the olive family and — alongside its precursor oleuropein — the centerpiece of the Mediterranean-diet cardiovascular-protection mechanism. Hydroxytyrosol has the singular distinction of being the only natural polyphenol with an EFSA-approved cardiovascular health claim. Since 2012, the European Food Safety Authority has authorized the claim that "olive oil polyphenols contribute to the protection of blood lipids from oxidative stress" for any olive oil providing at least 5 mg of hydroxytyrosol and its derivatives per 20 g serving. No other polyphenol — not resveratrol, not EGCG, not curcumin, not any flavonoid — has received an approved EFSA Article 13.5 health claim. The EFSA decision was driven by the mechanistic depth and clinical reproducibility of the hydroxytyrosol oxidation-protection signal, anchored in the Covas 2006 EUROLIVE trial, which demonstrated dose-dependent reductions in circulating oxidized LDL in 200 healthy men given olive oils of increasing polyphenol content over three 3-week intervention periods.
The clinical case for hydroxytyrosol rests on four main evidence pillars. First, the EUROLIVE trial established that olive polyphenol content — not fatty-acid composition — drives LDL oxidation protection. Second, the PREDIMED cardiovascular primary-prevention trial (Estruch 2013 PMID 23432189 and 2018 reanalysis PMID 29897866) demonstrated that adding high-polyphenol EVOO to a Mediterranean dietary pattern reduced major cardiovascular events by 30% over a median 4.8-year follow-up in 7,447 high-risk adults — an effect size matching high-intensity statin therapy and attributable primarily to the hydroxytyrosol/oleuropein polyphenol load of the intervention oil. Third, a growing body of smaller RCTs with direct hydroxytyrosol isolates (Hytolive, Benolea) at 5–50 mg/day has shown consistent signals for improved endothelial function, reduced oxidized LDL, modest blood pressure reduction, and improved lipid profile. Fourth, the mechanistic literature is unusually deep for a food polyphenol — hydroxytyrosol is one of the best-characterized dietary antioxidants in terms of pharmacokinetics, phase-II metabolism, Nrf2 activation, and direct radical-scavenging kinetics.
Commercially, hydroxytyrosol is available as branded standardized ingredients from the olive supply chain. Hytolive (Genosa, Spain) is derived from olive mill wastewater via a patented aqueous extraction, standardized to 10–25% hydroxytyrosol, and has been the ingredient in most published hydroxytyrosol RCTs. Benolea (Frutarom/IFF) is olive-leaf-derived, standardized to similar hydroxytyrosol and oleuropein content. Olivactiv, Bioactive HT, and other branded HT ingredients occupy the same space. Consumer products range from low-dose cardiovascular blends (5–10 mg HT per capsule) to athletic-performance formulations (25–50 mg HT per serving). Prices run $0.20–$1.50 per mg of standardized HT, making dedicated hydroxytyrosol a premium-tier supplement relative to raw olive leaf extract or culinary EVOO. For most users, high-polyphenol EVOO (2–3 tablespoons daily) remains the most cost-effective and evidence-aligned hydroxytyrosol delivery vehicle; standardized HT supplementation is reserved for specific use cases where precise dose control, rapid absorption, or maximum polyphenol density is required.
The hydroxytyrosol literature also extends beyond cardiovascular medicine into neuroprotection (Parkinson's disease models, cognitive aging studies), metabolic disease (insulin sensitization, hepatic lipid reduction in NAFLD models and early clinical trials), athletic performance (exercise-induced oxidative stress, muscle recovery), skin biology (UV protection, fibroblast protection from oxidative damage), and emerging anti-cancer mechanistic work (particularly in colorectal and breast cancer preclinical models). The neuroprotective story is notable because hydroxytyrosol crosses the blood-brain barrier more readily than most dietary polyphenols — a consequence of its small size, catechol structure, and modest lipophilicity — and because dopaminergic neurons in the substantia nigra are uniquely vulnerable to oxidative stress from dopamine auto-oxidation, which hydroxytyrosol (as a structural cousin of dopamine) may help buffer. Clinical evidence in neurological disease is still preclinical and early-translational, but the mechanistic rationale is strong.
Hydroxytyrosol is best understood as the absorbed, bioavailable, pharmacologically active form of the olive polyphenol family. Oleuropein delivers it via hydrolysis; high-polyphenol EVOO delivers it as a matrix effect with oleocanthal and other secoiridoids; direct hydroxytyrosol isolates deliver it unmodified with maximum dose precision. For users who want a known, standardized polyphenol dose — particularly athletes, users with specific cardiovascular or metabolic indications, or those whose dietary EVOO intake is constrained — direct hydroxytyrosol supplementation is the cleanest approach. For routine cardiovascular protection within a Mediterranean pattern, high-polyphenol EVOO wins on cost, nutritional matrix, and cultural sustainability.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
Not yet available
Chemical data is being compiled for this compound.
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
Hydroxytyrosol has essentially no absolute contraindications, consistent with its status as a dietary polyphenol with centuries of population-scale consumption through olive oil intake. Relative contraindications and cautions:
True olive allergy. Rare but documented, often cross-reacting with olive pollen (a major Mediterranean aeroallergen). Users with confirmed olive fruit or olive pollen allergy with systemic reactions should avoid olive leaf extract and direct hydroxytyrosol isolates. Culinary EVOO use may be tolerated but should be discussed with an allergist. Mild oral allergy syndrome (perioral tingling, lip itching) with olives does not contraindicate supplemental use but warrants initiating at low doses and monitoring for progression.
Concurrent antihypertensive therapy. Hydroxytyrosol (and olive leaf extract) produces modest BP reductions (typically 3–8 mmHg systolic in normotensive or pre-hypertensive subjects, larger in the Susalit stage-1 hypertensive cohort). For users on multiple antihypertensive medications — ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, diuretics, or combinations — adding supplemental HT may produce additive BP effects, particularly orthostatic hypotension in elderly patients. Practical approach: start at the low end of the HT dose range (10 mg/day direct HT or 500 mg/day olive leaf extract), monitor home BP daily for 2–4 weeks, and coordinate dose adjustments with the prescribing physician. Orthostatic symptoms (lightheadedness on standing) require dose reduction of either HT or the prescription regimen.
Concurrent antidiabetic therapy. Modest insulin-sensitizing effects may add to insulin, sulfonylureas, meglitinides, or SGLT2 inhibitors. Monitor blood glucose during the first 2–4 weeks of HT initiation, particularly if you have frequent hypoglycemia episodes on your current regimen. The signal is modest; clinically significant hypoglycemia from HT supplementation is rare.
Pregnancy. Dietary EVOO intake during pregnancy is universally safe and probably beneficial — consistent with broader Mediterranean-diet epidemiology. Pharmacologic-dose supplemental hydroxytyrosol or olive leaf extract during pregnancy has not been formally studied. Avoid supplemental forms during pregnancy or discuss with an obstetrician; continue dietary EVOO intake.
Lactation. Dietary EVOO during lactation is safe and encouraged. Supplemental HT or olive leaf extract during lactation lacks formal evaluation; probably fine but should be discussed with the pediatrician, particularly in the first 3 months of breastfeeding.
Pediatric. No formal pediatric studies exist. Dietary EVOO and table-olive intake are safe and traditional in Mediterranean children. Supplemental HT is not recommended in children or adolescents without pediatrician oversight.
Bleeding disorders and anticoagulation. Weak anti-platelet activity at very high HT doses (>50 mg/day direct HT or >1500 mg/day olive leaf extract) may add to aspirin, NSAIDs, warfarin, or direct oral anticoagulants (DOACs). The clinical signal is essentially zero at standard doses and only weakly present at high doses. Warfarin users on high-dose supplementation should check INR 2–3 weeks after starting. DOAC users do not need formal monitoring at standard doses. Stop high-dose supplementation 7 days before major surgery as a standard precaution.
Severe hypotension or decompensated heart failure. Avoid adding HT supplementation if you have borderline-low BP or are actively being titrated on multiple cardiac medications for decompensated heart failure. Wait until the acute regimen is stable, then discuss addition with your cardiologist.
MAO inhibitors and tricyclic antidepressants — theoretical concern. Hydroxytyrosol is structurally similar to catecholamines and is metabolized in part via COMT and MAO. Theoretical interactions with MAO inhibitors (phenelzine, tranylcypromine, moclobemide) or tricyclic antidepressants could affect plasma catecholamine levels or serotonergic signaling. Clinical evidence for this interaction is absent — standard HT doses have not shown effects on BP extremes, heart rate, or mood biomarkers in trials. Initiate at low doses and monitor for adrenergic symptoms (palpitations, sweating, anxiety, BP lability) if on these medications.
Very high doses (>100 mg/day direct HT). Isolated case reports of palpitations, headache, or GI intolerance at high supplemental doses. Not a contraindication but a rationale to limit direct HT to 10–50 mg/day in most indications.
Contraindications that are NOT present: Liver or kidney disease (HT is well-tolerated in mild-moderate hepatic or renal impairment); cardiovascular disease broadly (HT is indicated, not contraindicated); diabetes (HT is adjunct, not contraindicated); pregnancy loss history (no signal); cancer history (no signal — HT is mechanistically neutral or favorable in most cancer models); autoimmune disease (no signal); prior statin intolerance (HT is fine alongside statins).
Drug interactions — minimal. Olive polyphenols are weak and clinically insignificant inhibitors of most CYP450 enzymes at supplemental doses. In contrast to grapefruit juice, olive oil and olive products do not meaningfully affect CYP3A4-metabolized drugs (calcium channel blockers, statins, immunosuppressants, many psychiatric medications). Theoretical weak inhibition of P-glycoprotein and OATP1A2 at very high HT doses could marginally affect absorption of narrow-therapeutic-index drugs like digoxin or fexofenadine — space dosing by 2–4 hours as a simple hedge if one of these is concurrent.
Red flags that warrant stopping. New orthostatic symptoms that don't resolve with dose reduction; unexplained easy bruising or bleeding on supplementation; new allergic symptoms (rash, urticaria, angioedema); unexplained hypoglycemia in diabetics; severe GI intolerance (persistent nausea, abdominal pain, diarrhea); palpitations or arrhythmias. Stop the supplement and consult your clinician before resuming.
Not a replacement for indicated prescription therapy. Hydroxytyrosol and olive leaf extract are adjuncts — not replacements — for prescription antihypertensives in stage-2 hypertension (BP >140/90), insulin in type-1 diabetes, statin therapy in high-ASCVD-risk individuals with elevated apoB, antiplatelets after acute coronary syndrome, or antibiotics in confirmed bacterial infections. They are valid adjuncts to prescription therapy with clinician coordination, but abrupt replacement of indicated drug therapy with polyphenol supplementation risks major adverse cardiovascular events.
Not contraindicated but commonly confused: Hydroxytyrosol is NOT the same as olive oil (it is the active polyphenol within it); NOT the same as oleuropein (it is the absorbed metabolite of oleuropein); NOT the same as hydroxychloroquine (a malaria/autoimmune drug with completely different pharmacology); NOT the same as tyrosine (an amino acid); NOT the same as dopamine, despite structural similarity. The grapefruit–drug interaction does NOT apply to olive products.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
No listings found for Hydroxytyrosol.
Related Compounds
View AllHesperidin
PolyphenolPreclinicalHesperidin is the signature flavanone glycoside of citrus fruit — specifically the 7-O-rutinoside of hesperetin — and it is the single most abundant flavonoid in the white pith and peel of sweet oranges, lemons, tangerines, and grapefruit.
Oleocanthal
PolyphenolPreclinicalOleocanthal — more precisely (-)-oleocanthal, or p-HPEA-EDA (para-hydroxyphenylethanol elenolic acid dialdehyde) — is the pungent phenolic secoiridoid that gives fresh, high-polyphenol extra-virgin olive oil its characteristic throat-biting, pepper-like sensation when swallowed.
Oleuropein
PolyphenolPreclinicalOleuropein is the signature secoiridoid glycoside of Olea europaea — the olive tree — and it is the single most important polyphenol responsible for the cardiovascular, anti-inflammatory, and metabolic benefits long associated with extra-virgin olive oil and with the broader Mediterranean diet.
View Full Dosage Guide →
Protocols, calculator & safety for Hydroxytyrosol
Research Score
2277 PubMed studies
Quality Indicators
Data Completeness
63%Research Credibility
Well-researched compound
Quick Facts
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is hydroxytyrosol, and how is it different from oleuropein?
Hydroxytyrosol (3,4-dihydroxyphenylethanol, HT) is a small catechol polyphenol — the smallest natural phenolic compound — produced by the olive tree. Structurally it is essentially 'dopamine without the amine,' with two adjacent phenolic hydroxyl groups on a benzene ring connected by a two-carbon ethyl bridge to a terminal alcohol. Oleuropein is a larger, glycosylated, bitter-tasting molecule — an ester of elenolic acid and hydroxytyrosol, linked to a glucose moiety — that is abundant in olive leaves (6–9% dry weight) and in young olives and high-polyphenol extra-virgin olive oil. When you consume oleuropein orally (from olive leaf extract or olive products), stomach acid and gut esterases rapidly hydrolyze it into hydroxytyrosol plus elenolic acid glucoside. The hydroxytyrosol is the molecule that actually reaches your bloodstream and mediates the systemic cardiovascular and metabolic effects attributed to olive polyphenols. Think of it this way: oleuropein is the delivery vehicle, hydroxytyrosol is the cargo. Direct hydroxytyrosol supplements (Hytolive, Benolea) bypass the hydrolysis step and deliver the active cargo directly, with the trade-off of higher price and loss of the olive matrix effects (oleocanthal, oleacein, and other secoiridoids that contribute independently). For most users, high-polyphenol EVOO delivers the most complete olive polyphenol matrix at the lowest cost.
Is the EFSA olive oil health claim for hydroxytyrosol specifically, or for olive oil in general?
The 2012 EFSA Article 13.5 health claim applies to olive oils that provide at least 5 mg of hydroxytyrosol and its derivatives (oleuropein complex and tyrosol) per 20 g serving. The claim language is 'olive oil polyphenols contribute to the protection of blood lipids from oxidative stress.' This is mechanistically about hydroxytyrosol and its pharmacological cousins — not about olive oil's monounsaturated fat, not about vitamin E in olive oil, not about 'Mediterranean diet' broadly. No other polyphenol anywhere in the human diet — not resveratrol, not curcumin, not EGCG, not quercetin, not any flavonoid — has received a positive EFSA Article 13.5 health claim. This reflects the unique depth and reproducibility of the hydroxytyrosol oxidation-protection clinical signal, anchored in the Covas 2006 EUROLIVE trial (PMID 16954359). Practically, the claim means a high-polyphenol EVOO delivering >250 mg/kg total polyphenols (in 20 g serving delivers >5 mg HT-equivalents) can carry the claim on its label in EU markets; lower-polyphenol oils cannot. US FDA has not authorized a parallel claim but the mechanistic and clinical evidence is identical.
Should I take direct hydroxytyrosol supplements, or is olive oil enough?
For most users, a high-polyphenol extra-virgin olive oil (2–3 tablespoons / 25–40 mL daily) is sufficient and evidence-aligned. This delivers 8–20 mg/day of hydroxytyrosol-equivalents within the lipid matrix that is itself cardioprotective (monounsaturated fat, phytosterols, α-tocopherol, squalene), at a cost of roughly $0.50–$1.50/day for premium EVOO. The PREDIMED cardiovascular outcomes trial (Estruch 2013 PMID 23432189) used dietary EVOO — not direct HT supplements — and achieved a 30% cardiovascular event reduction. Direct hydroxytyrosol supplementation (Hytolive or Benolea at 10–50 mg/day) makes sense for specific use cases: (a) athletic performance applications where precise polyphenol dosing around training is desired, (b) specific cardiovascular or metabolic indications (stage-1 hypertension, metabolic syndrome, NAFLD) where maximizing polyphenol density matters, (c) dietary contexts where regular EVOO intake is constrained (restaurant-heavy diet, travel, olive intolerance that still permits HT isolate), (d) longevity-oriented stacks where dose precision is part of the protocol. For general health and cardiovascular protection within a Mediterranean pattern, start with EVOO — it wins on cost, matrix effects, and cultural sustainability.
Does hydroxytyrosol help with exercise recovery or athletic performance?
The evidence is promising but small. A handful of RCTs in trained athletes have shown that hydroxytyrosol 25–50 mg/day for 4–8 weeks reduces markers of exercise-induced oxidative stress — lipid peroxidation byproducts (MDA, 8-iso-prostaglandin F2α), muscle damage markers (creatine kinase, myoglobin), and inflammatory cytokines in response to intense training. Whether this translates to better recovery, reduced delayed-onset muscle soreness, or improved performance outcomes is less clear — the effect sizes in performance metrics (time-to-exhaustion, power output, sprint performance) are small and inconsistent. HT is not a performance-enhancing ergogenic aid in the same category as caffeine, creatine, or beta-alanine; rather, it is a background antioxidant that may support tolerance of high training volumes. For athletes pursuing peak polyphenol protocols: HT 25 mg 60–90 min pre-training combined with L-citrulline 6–8 g; post-training recovery is better served by whole-food polyphenol-rich meals than additional supplementation. The anti-inflammatory signal is more reliably observed than the pure performance signal — consider HT part of the recovery and inflammation-management layer rather than a pre-workout ergogenic.
Can hydroxytyrosol replace my blood pressure medication?
For most BP patients, no — it is an adjunct, not a replacement. For stage-1 hypertension (130–140/80–90) in otherwise low-risk patients, olive leaf extract 500 mg BID (delivering ~75–100 mg/day absorbed hydroxytyrosol-equivalents) produced BP reductions similar to low-dose captopril 12.5–25 mg BID in the Susalit 2011 trial (PMID 21310600) — approximately -11/-5 mmHg from baseline at 8 weeks. For this specific population (early-stage hypertension, low overall ASCVD risk, high patient preference for non-pharmacologic approach), olive leaf extract or direct HT may be a reasonable first-line alternative or adjunct under physician oversight combined with lifestyle intervention (Mediterranean diet, exercise, weight loss, sodium reduction). For stage-2 hypertension (BP >140/90), established cardiovascular disease, diabetes, CKD, or high calculated 10-year ASCVD risk, HT is an adjunct to prescription antihypertensives — never a replacement. The cardiovascular risk of under-treated stage-2 hypertension is substantial and cannot be safely mitigated by polyphenol intake alone. Always coordinate with your prescribing physician; never abruptly stop prescription antihypertensives in favor of a supplement.
How does hydroxytyrosol compare to resveratrol, quercetin, or EGCG?
Different polyphenol subclasses with distinct mechanistic emphases — best used together rather than as substitutes. Hydroxytyrosol is a secoiridoid-derived simple phenol with the unique distinction of EFSA-approved cardiovascular claim and the strongest Level-1 outcomes trial (PREDIMED). Its primary strengths are direct LDL oxidation protection, endothelial eNOS support, Nrf2 activation, and exceptional safety/tolerability. Resveratrol and pterostilbene are stilbenes — the strongest SIRT1 activators, with emphasis on mitochondrial biogenesis and calorie-restriction-mimetic effects. Quercetin and fisetin are flavonols — focused on senolytic activity (selective clearance of senescent cells), mast-cell stabilization, and anti-inflammatory signaling. EGCG is a catechin — cardiovascular and metabolic effects with weight-loss and gene-expression modulation. Apigenin is a flavone — notable for CD38 inhibition to preserve NAD+ levels. Hesperidin is a flavanone — venotonic and endothelial-supportive. For a comprehensive polyphenol-longevity stack, combine subclasses: high-polyphenol EVOO + olive leaf extract or direct HT (secoiridoid), quercetin (flavonol), pterostilbene (stilbene), EGCG (catechin, separated from iron-rich meals), apigenin (flavone), hesperidin (flavanone), curcumin phytosome (curcuminoid). Each hits distinct nodes; the combination is more physiologically complete than any single agent.
Does hydroxytyrosol really cross the blood-brain barrier and protect neurons?
Yes, hydroxytyrosol crosses the blood-brain barrier readily — a consequence of its small size (molecular weight 154), catechol structure, and moderate lipophilicity. Preclinical rodent studies show detectable HT and its phase-II conjugates in brain tissue after oral dosing, with accumulation in regions vulnerable to oxidative stress (substantia nigra, hippocampus, cortex). Rodent models of Parkinson's disease (MPTP-induced dopaminergic neuronal loss), Alzheimer's disease (amyloid-beta overexpression models), and cerebral ischemia-reperfusion injury show consistent neuroprotective effects of HT at 5–20 mg/kg/day oral dosing. Mechanisms include direct BBB-penetrant antioxidant activity, Nrf2 activation in neurons and microglia, reduced neuroinflammation, preservation of mitochondrial function in dopaminergic neurons, and potential reduction of dopamine auto-oxidation stress (since HT is structurally similar to dopamine and may 'buffer' dopamine-related oxidative chemistry). Clinical evidence in human neurological disease is still preclinical-to-early-translational — small pilot studies in mild cognitive impairment and early Parkinson's have shown acceptable safety but have not generated definitive efficacy data. The preclinical case is strong enough that several Phase I/II neurological trials are planned. For users with neurodegenerative-risk factors (APOE4, family history of Alzheimer's or Parkinson's), incorporating HT via high-polyphenol EVOO or supplemental forms is a low-risk intervention with plausible long-term benefit, but it is not a substitute for evidence-based neurological care.
How long does hydroxytyrosol stay in your system after a dose?
Short. Oral hydroxytyrosol is rapidly absorbed (Cmax within 0.5–1 hour of oral dosing) and rapidly conjugated in enterocytes and liver to hydroxytyrosol-4'-glucuronide, hydroxytyrosol-3'-sulfate, and minor 3'-O-methyl-hydroxytyrosol (homovanillic alcohol). The elimination half-life of the parent and primary conjugates is approximately 1–4 hours, with urinary excretion as the primary route. By 8–12 hours post-dose, circulating levels return to baseline. This rapid turnover means hydroxytyrosol's 'blood level' is transient and daily consistent intake matters more than single-dose peaks. The practical implication: the Nrf2 priming effect and cumulative antioxidant enzyme upregulation (HO-1, NQO1, glutathione synthesis) are the durable benefit — not the brief radical-scavenging window of an individual dose. For divided dosing, BID (twice daily) captures most of the benefit; TID (three times daily) may be slightly better for sustained plasma levels but adds complexity without clear clinical superiority. Continuous daily consumption (food + supplement) is the evidence-aligned pattern.
Can I use hydroxytyrosol on my skin for antioxidant or anti-aging effects?
Topical hydroxytyrosol is used in some cosmetic formulations for its antioxidant, UV-protective, and anti-inflammatory properties, and the skin biology literature supports these effects in vitro (HT protects keratinocytes and fibroblasts from UV-induced oxidative damage). However, topical application delivers negligible systemic hydroxytyrosol — you will not achieve cardiovascular or metabolic benefits from a face cream. Topical HT is a cosmetic application, not a therapeutic one. If you want systemic benefits (cardiovascular, metabolic, neurological), use dietary EVOO or oral HT supplements. If you want skin-specific antioxidant support, a hydroxytyrosol-containing serum or cream may be a reasonable part of an evidence-informed skincare routine alongside topical vitamin C (L-ascorbic acid), retinol or retinoids, niacinamide, and adequate sunscreen — but it is not a replacement for sunscreen, and the clinical evidence base for topical HT as an anti-aging intervention is less robust than for retinoids or vitamin C.
What should I look for when choosing a hydroxytyrosol supplement?
Three criteria in priority order. First, standardized content: the label should specify the hydroxytyrosol content in mg per serving (for direct HT supplements) or the oleuropein percentage (for olive leaf extracts — aim for 15–20% oleuropein standardization, which corresponds to clinical-trial dosing). Products without specified polyphenol content are not reliably dosable and should be avoided. Second, branded ingredients for direct HT: Hytolive (Genosa, Spain) and Benolea (Frutarom / IFF) are the two established branded HT ingredients with published clinical trials behind them. Products using these branded ingredients are more reliable than generic 'hydroxytyrosol' with unspecified source. Third, quality manufacturing: GMP certification, third-party testing (USP, NSF, ConsumerLab), reputable brands with a track record in cardiovascular or longevity supplements. For direct HT isolate: Life Extension Hydroxytyrosol (Hytolive), specialty sports-nutrition brands using Hytolive or Benolea. For olive leaf extract: Barlean's Olive Leaf Complex, Gaia Herbs Olive Leaf (Standardized), Comvita Olive Leaf Extract, NOW Foods Olive Leaf. For premium high-polyphenol EVOO (the preferred delivery vehicle for most users): McEvoy Ranch, California Olive Ranch Destination Series, Fresh-Pressed Olive Oil Club (T.J. Robinson), Laudemio Frescobaldi. Start with dietary EVOO unless you have a specific reason for the isolated supplement form.
Research Tools
Related Compounds
View AllHesperidin
PolyphenolPreclinicalHesperidin is the signature flavanone glycoside of citrus fruit — specifically the 7-O-rutinoside of hesperetin — and it is the single most abundant flavonoid in the white pith and peel of sweet oranges, lemons, tangerines, and grapefruit.
Oleocanthal
PolyphenolPreclinicalOleocanthal — more precisely (-)-oleocanthal, or p-HPEA-EDA (para-hydroxyphenylethanol elenolic acid dialdehyde) — is the pungent phenolic secoiridoid that gives fresh, high-polyphenol extra-virgin olive oil its characteristic throat-biting, pepper-like sensation when swallowed.
Oleuropein
PolyphenolPreclinicalOleuropein is the signature secoiridoid glycoside of Olea europaea — the olive tree — and it is the single most important polyphenol responsible for the cardiovascular, anti-inflammatory, and metabolic benefits long associated with extra-virgin olive oil and with the broader Mediterranean diet.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
